Six Sacramento City Unified campuses will offer African American U.S. History for graduation credit starting this fall.
England and Belgium rallied from early deficits and the U.S. held on despite a red card, winning Wednesday to clear the first ...
Twenty years ago, Al Gore’s “An Inconvenient Truth” hit American theaters and rewrote the climate conversation overnight. The ...
A federal judge is demanding answers from the Kennedy Center about delays in providing an update on its operations, programming and renovation plans. U.S. Di ...
The 2026 NBA Draft has a chance to go down as an all-timer. The top of the class is what makes this group special, with A.J. Dybantsa, Darryn Peterson, Cameron Boozer, and Caleb Wilson all looking ...
Sacramento-area leaders launch effort for MLB expansion team; $1.8B secured for 50-acre stadium site
DIRECTOR MICHELLE DAPPER BREAKS DOWN WHAT IT WILL TAKE TO BRING MORE BASEBALL TO OUR AREA. WELL, THEY’RE CALLING IT THE SACRAMENTO PITCH. SACRAMENTO AND WEST SACRAMENTO JOINING FORCES TO LURE A MAJOR ...
OptiTROP-Lung05 randomized 413 untreated, PD-L1 ≥1% advanced NSCLC patients without EGFR/ALK alterations to sac-TMT+pembrolizumab versus pembrolizumab; primary endpoint was PFS. Median PFS was not ...
Sacramento is currently temporarily playing host to the Athletics. Scott Marshall / Getty Images When the itinerant Athletics chose the Sacramento area as their temporary home, local officials hoped ...
CHENGDU, China, May 21, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data Monitoring ...
A new treatment for endometrial cancer demonstrated strong potential in a Phase 3 clinical trial. Drugmaker Merck announced Monday that the investigational drug sacituzumab tirumotecan (sac-TMT) met ...
Sacituzumab tirumotecan significantly improved progression free survival and overall survival compared with chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results